Health
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
SAN JOSE, Calif., NANJING, China and SHANGHAI, May 28, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today thatChina's National Medic...
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy(NAC)for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases announced that ANTICIPATE Study will be presented at the...
ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017
SHANGHAI, May 27, 2022 /PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, today announced that an abstract detailing data from a Phase I study(P...
Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022
Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures Golidocitinib (DZD4205) demonstrates enormous potential for peripheral T-cell lymphoma DZD1516 exemplifies full BBB-penetration in patie...
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its seven clinical abstracts selected by the ...
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
* Lunit to showcase 7 poster presentations and 4 online publications, the company's largest publication set at ASCO to date * Findings demonstrate the practical effectiveness of Lunit's AI solutions in the pathological assessment of tumors across more than 16 primary cancer types SEOUL, South...
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
- Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity - Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression correlates with clini...
Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron
SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio companies have had great progress. Anji Pharma Complete...
Jelenew sponsors the amfAR Gala Cannes charity dinner of the American Foundation for AIDS Research to help global AIDS research
Jelenew x Stéphane Rolland cycling pants-dress newlook will show up at the
fashion show " Let's get married " and then be auctioned
CANNES, France, May 26, 2022 /PRNewswire/ -- American cycling brand Jelenew
Dr Neal Shore joins Clarity's Clinical Advisory Board
SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that DrNeal Shore has joined Clarity's Clinical Advisory Board (C...
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. andChina, respectively, in a Phase Ib/III cli...
111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow
SHANGHAI, May 26, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform
SHANGHAI and BRUSSELS, May 26, 2022 /PRNewswire/ -- Full-Life Technologies ("Full-Life") today announced it completed a$37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financ...
Bridge Biotherapeutics to Present at the 2022 BIO International Convention
SEONGNAM, South Korea, May 25, 2022 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentationon Thursday, June 16 at the 2022 BIO ...
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...
Infobird Digital Engagement Solutions Help Dental Practices Grow and Modernize
SaaS solutions to provide digitalized customer engagement to enhance working efficiency, customer experience and to increase customers lifelong value BEIJING, May 25, 2022 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD) ("Infobird" or the "Company"), a leading provider of AI-powered customer en...
SeekIn Receives CE Mark Approval for SeekInClarity™ Cancer Treatment Response Monitoring Kit
First-of-its-Kind blood-based pan-cancer treatment response monitoring test SHENZHEN, China, May 25, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (ConformitéEuropéenne) Mark approval for SeekInClarityTM Cancer Treatm...
Happiness Development Entered into Agreement for Sales up to 2000 Electric Vehicles
NANPING, China, May 25, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production and sale of nutraceutical and dietary supplements, providing e-commerce sales and marketing solutio...
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announcedthat it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inAustralia. This study will evaluate ...
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 350 media titles]
2024-09-18 11:30FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
[Picked up by 283 media titles]
2024-09-19 14:00Watsons-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
[Picked up by 274 media titles]
2024-09-19 08:00MediSun Energy Teams Up with EEIC to Strengthen UAE's Water Security and Advance Sustainable Energy Solutions
[Picked up by 267 media titles]
2024-09-18 09:15